• I performed my undergraduate studies in biochemistry and molecular biology at Pennsylvania State University (B.Sc, 2002). For graduate studies I trained with John Kearney, Ph.D. at the University of Alabama at Birmingham (Birmingham, AL). My thesis research focused on understanding the development of serologic and B cell memory to the T cell independent, type 2 antigen alpha 1->3-dextran. After obtaining my Ph.D. in microbiology and immunology, I took a 4 year hiatus from research to obtain my doctorate in veterinary medicine at Auburn University, College of Veterinary Medicine. While at Auburn I obtained additional training in cancer genetics and immunology under the guidance of Dr. Curtis Bird, Ph.D. My research in Dr. Bird’s lab focused on generating a mouse model of the canine immune system, permissible to engraftment of canine peripheral blood mononuclear cells derived from canine patients with mammary cancer. The goal of this work was to model patient immunity to an experimental autologous dendritic cell (derived from patients) – allogeneic canine mammary tumor vaccine. After obtaining my DVM, I went to Johns Hopkins to pursue a residency in veterinary anatomic pathology and postdoctoral research in cancer immunology and translational medicine. While at Johns Hopkins in the departments of Molecular and Comparative Pathobiology and Oncology, I completed my residency training in veterinary anatomic pathology and obtained additional training in tumor immunology and translational medicine with Dr. Leisha Emens (M.D., Ph.D.) My postdoctoral research in Dr. Emens lab focused on evaluating the therapeutic potential of the STING agonist ADU-S100 in combination with immune checkpoint blockade. After completion of my postdoctoral fellowship, I was appointed as a faculty member in the departments of Microbiology and Animal Resources Program where I currently serve as both an investigator in Microbiology and veterinary anatomic pathologist for ARP.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Observations on hydronephrosis after pig kidney transplantation in baboonsXenotransplantation.  29. 2022
    2022 The Genetically Engineered Heart as a Bridge to Allotransplantation in Infants Just Around the Corner?Annals of Thoracic Surgery.  114:536-544. 2022
    2022 Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I 2022
    2022 Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug DeliveryPharmaceutics.  14. 2022
    2022 Host Genetics But Not Commensal Microbiota Determines the Initial Development of Systemic Autoimmune Disease in BXD2 MiceArthritis and Rheumatology.  74:634-640. 2022
    2022 T and B lymphocyte dynamics after genetically-modified pig-to-baboon kidney xenotransplantation with an anti-CD40mAb-based immunosuppressive regimenTransplant Immunology.  71. 2022
    2022 Profound thrombocytopenia associated with administration of multiple anti-inflammatory agents in baboonsImmunity, Inflammation and Disease.  10. 2022
    2022 Mucociliary Transport Deficiency and Disease Progression in Syrian Hamsters with SARS-CoV-2 Infection. 2022
    2022 A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tractsHuman Vaccines and Immunotherapeutics.  18. 2022
    2022 Cardiac and Pulmonary Histopathology in Baboons Following Genetically-Engineered Pig Orthotopic Heart Transplantation 2022
    2022 Poly (acetyl, arginyl) glucosamine disrupts Pseudomonas aeruginosa biofilms and enhances bacterial clearance in a rat lung infection modelMicrobiology.  168. 2022
    2021 ATXN10 Is Required for Embryonic Heart Development and Maintenance of Epithelial Cell Phenotypes in the Adult Kidney and PancreasFrontiers in Cell and Developmental Biology.  9. 2021
    2021 Stable expression of the human thrombomodulin transgene in pig endothelial cells is associated with a reduction in the inflammatory responseCytokine.  148. 2021
    2021 Histopathology of pig kidney grafts with/without expression of the carbohydrate Neu5Gc in immunosuppressed baboonsXenotransplantation.  28. 2021
    2021 Initial evidence that blockade of the CD40/CD154 costimulation pathway alone is sufficient as maintenance therapy in xenotransplantationXenotransplantation.  28. 2021
    2021 A perspective on the potential detrimental role of inflammation in pig orthotopic heart xenotransplantationXenotransplantation.  28. 2021
    2021 Evidence suggesting that deletion of expression of N-glycolylneuraminic acid (Neu5Gc) in the organ-source pig is associated with increased antibody-mediated rejection of kidney transplants in baboonsXenotransplantation.  28. 2021
    2021 Immunological selection and monitoring of patients undergoing pig kidney transplantationXenotransplantation.  28. 2021
    2021 What Therapeutic Regimen Will Be Optimal for Initial Clinical Trials of Pig Organ Transplantation?Transplantation.  105:1143-1155. 2021
    2021 Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomasNeurosurgical Focus.  50:1-11. 2021
    2021 Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus. 2021
    2021 Pig kidney xenotransplantation: Progress toward clinical trialsClinical Transplantation.  35. 2021
    2020 Cutaneous lewisite exposure causes acute lung injuryAnnals of the New York Academy of Sciences.  1479:210-222. 2020
    2020 The final obstacle to successful pre-clinical xenotransplantation?Xenotransplantation.  27. 2020
    2020 The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade GliomasFrontiers in Surgery.  7. 2020
    2020 Inhibition of the NAD salvage pathway in schistosomes impairs metabolism, reproduction, and parasite survivalPLoS Pathogens.  16. 2020
    2020 Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigenOncoImmunology.  9. 2020
    2019 Indicators of impending pig kidney and heart xenograft failure: Relevance to clinical organ xenotransplantation - Review articleInternational Journal of Surgery.  70:84-91. 2019
    2019 Life-supporting Kidney Xenotransplantation from Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive RegimensTransplantation.  103:2090-2104. 2019
    2018 STING signaling: A key to therapeutic tumor immunityImmunotherapy.  10:729-731. 2018
    2017 A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized MiceCancer Immunology Research.  5:468-479. 2017
    2017 Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivoInternational Immunopharmacology.  46:112-123. 2017
    2015 A murine viral outgrowth assay to detect residual HIV type 1 in patients with undetectable viral loadsJournal of Infectious Diseases.  212:1387-1396. 2015
    2015 Immune targeting in breast cancerOncology (Williston Park, N.Y.).  29. 2015
    2015 Immune targeting in breast cancerOncology (Williston Park, N.Y.).  29:375-385. 2015
    2014 Engraftment of canine peripheral blood lymphocytes into nonobese diabetic-severe combined immune deficient IL-2R common gamma chain null miceVeterinary Immunology and Immunopathology.  157:131-141. 2014
    2012 A rapid and quantitative method for the evaluation of V gene usage, specificities and the clonal size of B cell repertoiresImmunotechnology : an international journal of immunological engineering.  376:143-149. 2012
    2012 Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cellsJournal of Immunology.  188:57-67. 2012
    2011 Membranous glomerulopathy in an adult patient with X-linked agammaglobulinemia receiving intravenous gammaglobulin 2011
    2011 Marginal zone B cells regulate antigen capture by marginal zone macrophagesJournal of Immunology.  186:2172-2181. 2011
    2009 Generation of B cell memory to the bacterial polysaccharide α-1,3 dextranJournal of Immunology.  183:6359-6368. 2009
    2006 Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cellsJournal of Immunology.  177:6815-6823. 2006
    2005 Marginal zone B cells in lymphocyte activation and regulationCurrent Opinion in Immunology.  17:244-250. 2005


    Year Title Altmetric
    2022 Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.  131-168. 2022
    2020 Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry.  1-20. 2020

    Research Overview

  • Evaluating the Roles of B cells and Antibody in Pancreatic Cancer Progression - Infiltrating pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States and it is one of the most fatal human malignancies, with an overall 5-year survival rate of less than 5%. Both response to standard-of-care and immune checkpoint therapies is poor requiring alternate strategies to induce patient-specific immune responses. In pancreatic cancer pro-tumorigenic macrophage, T regulatory cells, myeloid-derived suppressor cells, and tumor-associated fibroblasts are present within the tumor beginning at early pre-invasive stages of pancreatic cancer development. These cellular subsets inhibit T cell activation and CD8+ T cell recruitment into the tumor. Additional studies have implicated tumor infiltrating B cells as a tumor-promoting subset required for epithelial carcinoma progression enhancing tumor cell survival and contributing to chronic inflammatory cues critical to tumor progression. Our preliminary findings in mouse models of Kras-driven pancreatic cancer indicate that antibodies appear to play an important role in promotion of tumor immunity and limiting metastasis. The major goal of my current research focus is to determine requirements for antibody-driven, pancreatic tumor-specific immunity using mouse models that closely recapitulate disease progression observed in patients. Furthermore we intend to elucidate antibody-dependent and independent mechanisms that promote and inhibit cancer progression using spontaneous, orthotopic, and models that mimic metastatic disease using syngenic pancreatic ductal adenocarcinomna cell lines derived from spontaneously formed neoplasms. Ultimately the findings from these studies will be utilized to test novel and modifications to currently existing treatments to harness the therapeutic capabilities of antibody and limit the immune suppressive effects of B cells in the pancreatic tumor microenvironment with the goal of providing novel therapies capable of successful translation into the clinic. As a comparative pathologist for ARP, I also contribute pathology support to research projects bridging a wide span of research areas, including cancer, autoimmunity, mucosal and transplant immunology. These collaborations involve rodent, porcine, primate models and canine cancer patients. The goal of these collaborations is to provide comparative pathology support to investigators in their respective projects.
  • Investigator On

  • Canine Immuno Neurotherapeutics  awarded by National Cancer Institute/NIH/DHHS
  • Genetically - Engineered Pig Organ Transplantation in Baboons: Immunological and Functional Studies  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Immune Interaction with the Mucus-Associated Microbiota  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Investigations of a Self-amplifying RNA Vaccine Against Covid-19  awarded by ACCESS TO ADVANCED HEALTH INSTITUTE
  • Loss of NF1 drives Hormone Dependent Mammary Carcinogenesis in a Rat Model with Intact Immune System  awarded by National Cancer Institute/NIH/DHHS
  • NF1 Experimental Mouse Models: Histopathology and Neuroanatomical Phenotyping  awarded by GILBERT FAMILY FOUNDATION'S GENE THERAPY INITIATIVE, LLC (GTI)
  • Private Grant  awarded by MEISSA VACCINES INC
  • Skin Grafting From ‘9-Gene’ Genetically Engineered Pigs in the Treatment of Burns: An Experimental Study in Monkeys.  awarded by DOD - Department of Defense
  • Skin Grafting from 9-Gene Genetically Engineered Pigs in the Treatment of Burns: An Experimental Study in Monkeys  awarded by DOD - Department of Defense
  • Skin Grafting from 9-Gene Genetically Engineered Pigs in the Treatment of Burns: An Experimental Study in Monkeys  awarded by DOD - Department of Defense
  • Targeted Neuroendocrine Cancer Therapy using Verrucarin A  awarded by National Cancer Institute/NIH/DHHS
  • UAB Pilot Center for Precision Animal Modeling (C-PAM)  awarded by NIH - OFFICE OF THE DIRECTOR
  • UAB Pilot Center for Precision Animal Modeling (C-PAM) - Disease Modeling Unit  awarded by NIH - OFFICE OF THE DIRECTOR
  • mtDNA Depleter Mouse for Decoding Mitochondrial Regulation of Diverse Organs  awarded by NIH - OFFICE OF THE DIRECTOR
  • Education And Training

  • Johns Hopkins, School of Medicine Oncology, Postdoctoral Fellowship
  • Doctor of Veterinary Medicine, Auburn University 2013
  • Doctor of Philosophy in Microbiology, University of Alabama at Birmingham 2009
  • Bachelor of Science or Mathematics in Biochemistry and Molecular Biology, The Pennsylvania State University 2002
  • Full Name

  • Jeremy Foote